ADC Therapeutics SA (ADCT) - Dilution Analysis

S-3 filing: This is an S-3 filing for ADC Therapeutics SA, registering 9,834,776 common shares for resale by selling shareholders, potentially generating up to $37.5 million from warrant exercises for the company's working capital and general corporate purposes.

S-3/A filing: SEC filing for a primary offering of securities, outlining the registrant's commitment as a seller to purchasers in the initial distribution.

S-3 filing: This S-3 filing registers the resale of common shares and shares issuable upon exercise of pre-funded warrants previously sold in a private placement.

10-Q filing | 123.9M shares outstanding

8-K filing: ADC Therapeutics SA will sell 11,250,000 common shares at $4.00 per share and pre-funded warrants to purchase 3,846,153 common shares at $3.90 per pre-funded warrant in a $60.0 million private placement expected to close on October 27, 2025. ($60.0M proceeds)

10-Q filing | 113.7M shares outstanding

S-3 filing: This is an S-3 filing for ADC Therapeutics SA, where selling shareholders may offer an aggregate of 27,726,052 common shares from time to time.

8-K filing: ADC Therapeutics SA entered into securities purchase agreements for a $100 million private placement, selling 13,031,161 common shares at $3.53 per share and pre-funded warrants to purchase 15,734,267 common shares at $3.432 per pre-funded warrant. The private placement is expected to close on June 16, 2025.

10-Q filing | 107.2M shares outstanding

10-K filing | 97.2M shares outstanding

10-Q filing | 104.8M shares outstanding

S-3 filing: ADC Therapeutics SA may offer and sell from time to time, in one or more offerings, up to $300,000,000 of any combination of securities including common shares, debt securities, warrants, subscription rights, purchase contracts and units.

10-Q filing | 95.7M shares outstanding

8-K filing: ADC Therapeutics SA completed an offering of 13,411,912 common shares and pre-funded warrants to purchase 8,163,265 common shares at $4.90 and $4.812 respectively, with gross proceeds of approximately $105.0 million. ($105.0M proceeds)

10-Q filing | 82.6M shares outstanding

POS AM filing: This is a POS AM filing for the resale of up to 1,260,863 common shares by selling shareholders.

POS AM filing: ADC Therapeutics SA may offer and sell from time to time, in one or more offerings, up to $300,000,000 of any combination of securities including common shares, debt securities, warrants, subscription rights, purchase contracts and units.

POS AM filing: This prospectus relates to the resale of up to an aggregate of 4,412,840 common shares by the selling shareholders identified in this prospectus.

10-K filing | 81.7M shares outstanding

F-3 filing: ADC THERAPEUTICS SA files an F-3 form to offer and sell up to $300,000,000 of common shares, debt securities, warrants, subscription rights, purchase contracts and units.

20-F filing | 80.6M shares outstanding

F-3 filing: The filing relates to the resale of up to an aggregate of 4,412,840 common shares by the selling shareholders.

F-3 filing: This F-3 filing relates to the potential resale of 1,260,863 common shares by selling shareholders, including shares issuable upon exercise of warrants, with the company not receiving any proceeds from these sales.

POS AM filing: Post-Effective Amendment No. 1 to deregister all securities that had been registered for sale on the Registration Statement that remain unsold under such Registration Statement.

20-F filing | 76.8M shares outstanding

20-F filing | 76.7M shares outstanding

F-1 filing: This is an F-1 filing describing a $115 million facility agreement with Deerfield, which includes two tranches of convertible loans. The first tranche is for $65 million and the second tranche is for $50 million, subject to regulatory approval.

F-1 filing: The company entered into a $115.0 million Facility Agreement with Deerfield Partners, L.P. to extend senior secured convertible term loans in two separate disbursements.